This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2010 Remove 2013 Remove DEA Remove Packaging
article thumbnail

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP advocates for robust regulation regarding labeling and child-proof packaging of all marijuana and cannabinoid products. Due to the Schedule I classification by the Drug Enforcement Agency (DEA), researchers seeking to investigate health effects associated with cannabis must follow a regimented application process.

Cannabinoids 40
Cannabinoids Marijuana Research and Development Access 40
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. British Journal of Nutrition (2010), 104, 803–806. References.

Extraction 73
Extraction Pharmaceutical CBD Epilepsy 73
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024